A Rising Bar for Biologic Purity

Yield and speed often get the headlines in biologics manufacturing. But the metric that can ultimately decide whether a therapy reaches patients is purity and how well a downstream process clears everything that isn't the drug itself.

As biologics have grown more complex, the standards around purity have tended to grow with them. The expectations that worked for a monoclonal antibody program a decade ago may not be the expectations a gene therapy program faces today. Traditional approaches can start to show their age, and manufacturers who built their downstream processes around older standards may find that "clean enough" isn't quite what it used to be.

What "pure enough" can mean today

Most conversations about purity in biologics come back to four categories of impurities that shouldn't be in the final product.

1. Leftover cell material

The small bits of protein left behind from the cells used to manufacture the drug. Even tiny amounts may cause immune reactions or affect how the drug performs. Expectations here have tended to shift over time toward more detailed monitoring, lower thresholds, and closer attention to specific high-risk pieces, not just a single average number.

2. Genetic material

Leftover DNA from the host cells used in manufacturing. Safety considerations around trace amounts have led to strict regulatory limits. There's also a newer wrinkle: when the drug itself is genetic material (as in mRNA or plasmid DNA therapies) separating product from contaminants can be considerably harder, because they look chemically similar.

3. Endotoxin

A contaminant from bacterial cells that can trigger fever and inflammation. The limits here aren't a moving target the way other impurity classes can be, but a single batch failure can still mean lost months. Endotoxin can sneak in through feed streams, hold steps, and even single-use components, so it tends to need attention at every stage rather than at any one step.

4. Product variants

The slightly different versions of the drug that can form during manufacturing: fragments, clumps, or misassembled forms of the intended molecule. They can reduce effectiveness or contribute to immune responses. Larger, more complex molecules tend to produce more of them, which is part of why advanced biologics can be harder to purify than the drugs they often follow.

Why it's getting harder

Several trends seem to be pushing the bar upward at the same time.

Newer therapies tend to be larger and more delicate, which means tools that worked well for older biologics may struggle with today's molecules. New modalities (gene therapies, RNA therapies, cell therapies) can introduce contaminants that older platforms weren't originally designed to handle. And regulators increasingly look for thoughtful justification of process choices rather than reliance on familiar templates.

Each of these on its own would likely be manageable. Stacked together, they can make the same level of purity that satisfied a regulatory reviewer five years ago look noticeably thinner today.

What strong purification can look like today

A robust purification process tends to be less about any single heroic step and more about how the whole train is designed.

1. Layered cleanup

A single step rarely removes everything. A thoughtful design tends to combine steps that catch different impurities in different ways. The more those steps complement each other, the more margin a process can have when an impurity profile shifts unexpectedly.

2. Consistency across batches

A process that performs well on average but drifts at the edges can create downstream problems including investigations, retests, and delays. Choosing technologies known for consistent performance can reduce that variability and shorten the gap between a campaign that goes smoothly and one that doesn't.

3. Designed with today's molecules in mind

Some downstream tools were designed decades ago for simpler drugs. Tools developed with modern biologics in mind may hold up better as standards continue to evolve, simply because they were built for the molecules now driving the industry. Membrane chromatography is one example. Its convective format was developed with larger, more delicate biologics in mind, and it is well suited to clearing the kinds of large impurities, such as residual host-cell DNA, viral particles, and aggregates, that newer therapies tend to carry.

Key takeaways

·       The definition of "clean enough" can keep moving as therapies get more complex.

·       Four areas tend to drive most of the purity conversation: leftover cell material, genetic material, endotoxin, and product variants.

·       Strong purification often looks layered, consistent, and built for the molecules of today.

·       The technology choices made in development can shape how much room a process has when the bar moves again.

Ready to learn more?

See how Purexa™ products can help manufacturers meet today's standards.